Brian Maas



McLaughlinALUM_40Under40_Logo-white-01.pngBrian Maas
PharmD '15  |  Jacksonville, FL

COMPANY: Merck & Co., Inc
INDUSTRY: Pharmaceutical


Dr. Brian Maas received his PharmD from the University of Florida College of Pharmacy in 2015. He went on to complete a fellowship in pharmacometrics at the University of North Carolina College of Pharmacy and IQVIA, with a research focus on pharmacokinetics of HIV antiretrovirals and modeling monoclonal antibody pharmacokinetics. Dr. Maas also completed an ORISE fellowship at the Office of Clinical Pharmacology at FDA where he specialized in pediatric research. 

Dr. Maas joined Merck in 2017 as a scientist in the quantitative pharmacology and pharmacometrics group. Since then, he has contributed to the development and approval of several infectious disease assets, including raltegravir for HIV and molnupiravir for COVID-19. Dr. Maas specializes in using modeling to accelerate drug development and increase the probability that clinical trials are successful. In his current role as a Scientific Director, Dr. Maas oversees the clinical pharmacology strategy for several compounds currently under development for RSV, influenza, and HIV. 

Dr. Maas is also passionate about giving back to the scientific community. He has co-authored over a dozen peer-reviewed publications and delivered several scientific talks at conferences. Dr. Maas serves as a peer-reviewer for the Journal of Clinical Pharmacology and an abstract reviewer for the International Society of Pharmacometrics. He has mentored several interns, fellows, and PharmD students. He is currently serving as the mentor for a postdoctoral researcher. 

In his free time Dr. Maas enjoys spending time with his family, playing soccer, hiking, and exploring different types of coffee.